Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.69 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8901408 | 0.89 | ACHE (0.60) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL4003983 | 0.85 | ACHE (0.73) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL11616794 | 0.83 | ACHE (0.71) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL4003986 | 0.83 | GRM5 (0.73) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL10983933 | 0.83 | ACHE (0.71) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL7129676 | 0.82 | HPGD (0.79) | ACHEL3MBTL1HPGDSIGMAR1KMT2A | |
| SCHEMBL252026 | 0.82 | HPGD (0.79) | ACHEL3MBTL1HPGDSIGMAR1KMT2A | |
| SCHEMBL409005 | 0.81 | ACHE (0.69) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL8988831 | 0.81 | ACHE (0.69) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL1673861 | 0.81 | MAPT (0.73) | ACHEEPHX1L3MBTL3L3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0968182-B1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
| EP-0968182-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| CN-1227540-A | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | DARWIN DISCOVERY CO LTD (GB) | 1999-09-01 | — | — | CN | disclosed |
| WO-1998005635-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1998-02-12 | — | — | WO | disclosed |
| US-5246946-A | Antiarrhythmia agents and cardiovascular disorders | EISAI CO., LTD. (JP) | 1993-09-21 | — | — | US | disclosed |
| EP-0304888-B1 | SULFONAMIDOLPHENYL DERIVATES AND THERAPEUTIC AND PREVENTIVE AGENTS FOR ARRYTHMIA CONTAINING SAME | Eisai Co., Ltd. (JP) | 1992-11-11 | — | — | EP | disclosed |
| US-5162347-A | Piperidine derivatives and therapeutic and preventive agents for arrhythmia containing same | EISAI CO., LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| US-5082850-A | PIPERIDINE DERIVATIVES AND THERAPEUTIC AND PREVENTIVE AGENTS FOR ARRHYTHMIA CONTAINING SAME | EISAI CO., LTD. (JP) | 1992-01-21 | — | — | US | disclosed |
| US-4977165-A | Piperidine derivative and therapeutic and preventive agents for arrhythmia containing same | EISAI CO., LTD. (JP) | 1990-12-11 | — | — | US | disclosed |
| EP-0304888-A1 | Sulfonamidolphenyl derivates and therapeutic and preventive agents for arrythmia containing same | Eisai Co., Ltd. (JP) | 1989-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | ACHE 1513/4885EPHX1 1453/4885L3MBTL3 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.